

ASX Announcement

19 October 2026

BCAL Diagnostics presents BREASTESTplus research at International Lipidomic Conference

Highlights

- **BCAL's research underpinning BREASTESTplus™ 2 has been presented as a scientific poster at the Australian Lipid Meeting and International Lipidomic Society Conference in Perth.**
- **The research provides a scientific foundation for the continued development of BREASTESTplus™**
- **BCAL is a global pioneer in commercialising lipid-based cancer detection technology.**
- **The *Clinical Translation of Targeted Lipidomics: Validation of BREASTESTplus™ 2 for Early Breast Cancer Detection* Poster is available here**

https://www.bcaldiagnostics.com/wp-content/uploads/2026/10/ALM7_5.iLS_2026.pdf

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for early detection of cancer, has presented a poster on scientific research underpinning BREASTESTplus™ 2 at the Australian Lipid Meeting and International Lipidomic Society Conference, Perth, 18–21 October 2026. The research traces the development of BCAL's blood-based breast cancer detection technology, from the discovery of lipid biomarkers associated with breast cancer through to assay development and validation.

BCAL is a global pioneer in commercialising lipid-based cancer detection technology. Its BREASTESTplus™ test is believed to be the first commercially available cancer detection test globally to use blood lipid biomarkers, translating advances in lipidomic research into a diagnostic tool available to patients.

The poster, titled *Clinical Translation of Targeted Lipidomics: Validation of BREASTESTplus™ 2 for Early Breast Cancer Detection*, outlines the scientific methodology supporting the development and validation of the test.

The Australian Lipid Meeting and International Lipidomic Society Conference brings together two major scientific gatherings focused on advancing lipid research. The joint conference unites researchers, scientists, clinicians and industry leaders from around the world to share discoveries, promote collaboration and explore the latest developments in lipidomics, lipid biology and related technologies.

Presenting BCAL's research at this conference provides an opportunity to share the science and methodology behind BREASTESTplus™ 2 with an international scientific audience, supporting greater awareness of the Company's technology and its potential clinical applications.

BCAL CEO Anne-Louise Arnett said, "The science underpinning our technology has been built through years of research, from identifying the lipid biomarkers associated with breast cancer to developing and validating the methodology behind the test. Sharing this work with the broader scientific community is an important step in building awareness, encouraging scientific engagement and strengthening the evidence base supporting our technology."

The *Clinical Translation of Targeted Lipidomics: Validation of BREASTESTplus™ 2 for Early Breast Cancer Detection* Poster is available here https://www.bcaldiagnostics.com/wp-content/uploads/2026/10/ALM7_5.iLS_2026.pdf

This announcement has been approved for release by the Board of BCAL.

ENDS

For further information:

Anne-Louise Arnett
Chief Executive Officer
aarnett@bcaldiagnostics.com

About BCAL Diagnostics

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTEST_{plus}™ as a ‘rule-out’ test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTEST_{plus}™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.